483
FujiFilm Diosynth Biotechnologies U.S.A., Inc.FujiFilm Diosynth Biotechnologies U.S.A., Inc. – FDA 483, Feb 10, 2023
Record Details
An FDA inspection of Fujifilm Diosynth Biotechnologies USA, Inc. in Morrisville, NC, a drug substance manufacturer, revealed significant deficiencies in their quality system. Observations included the absence of a written quality agreement defining responsibilities for drug substance quality, a lack of established procedures for reporting biological product deviations, and insufficient studies to verify endotoxin clearance monitoring during purification.
- Inspection date
- February 10, 2023
- Product type
- drugs
View Company Profile
ID · 4195691b-fc0e-45b6-8d70-bbfc800e6672
Other documents for FujiFilm Diosynth Biotechnologies U.S.A., Inc.
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.